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It is well documented that deregulation of MYC leads to
tumor development, yet many aspects of this process are
only partially understood. We have established a transgenic
mouse model in which c-MYC is conditionally expressed in
lymphoid cells using the tetracycline-regulated system of
gene regulation. Mice with continuously expressed trans-
genic c-MYC died of invasive T- or B-cell lymphomas within 4
months. Lymphomas developing in transgenic mice were
c-MYC dependent since doxycycline treatment led to tumor
regression. Using transplantation of established tumor cell
lines labeled with GFP, we followed the fate of neoplastic
cells in recipients upon MYC inactivation. This approach al-
lowed us to elucidate both apoptosis and differentiation as
mechanisms of tumor elimination. Comparative genomic hy-
bridization (CGH) and FISH analyses were performed in
order to analyze possible chromosomal aberrations induced
by c-MYC. We observed that overexpression of c-MYC is
sufficient to induce recurrent patterns of genomic instability.
The main observation was a gain of genomic material that
corresponded to chromosome 15 in several T-cell tumors,
which could be identified as trisomy.
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Since the first description as the cellular homologue of the
transforming sequences of the avian myelocytomatosis retrovirus,1
many properties of the c-MYC (MYC) protooncogene have been
described. The product of MYC oncogene is a bHLHZip transcrip-
tion factor that is conserved from Xenopus to human.2 Owing to
the presence of the HLH and Zip motifs, MYC is able to partici-
pate in various protein-protein interactions.3–7 The prototype MYC
transcription factor forms a heterodimer with the related protein
MAX.8,9 It has been shown that both activation and repression of
transcription could be mediated by MYC.10 In general, MYC
expression correlates tightly with the proliferative potential of a
cell: in quiescent cells, expression is virtually undetectable,
whereas upon mitogen stimulation, there is a rapid and transient
burst in mRNA and protein levels.11 It seems that MYC plays a
role in cell cycle regulation, differentiation, apoptosis, metabolism,
cell adhesion and regulation of hematopoietic homeostasis.12–16
Expression of MYC is altered in a wide variety of human and
animal tumors including breast, colon and cervical carcinomas,
small cell lung carcinomas, osteosarcomas, glioblastomas, my-
eloid leukemias and lymphomas.17 MYC is activated in these
tumors by a variety of genetic alterations, e.g., chromosomal
translocations, retroviral transduction, proviral insertion and gene
amplification. Several transgenic models confirmed that MYC
overexpression leads to tumorigenesis in different tissues.18–22
Results obtained with these transgenic models suggested that the
effect of MYC on cell fate depends on cell type, stage of differ-
entiation and physiological environment.
Genomic instability is frequently observed in a diversity of
tumors and correlates with the selection of the malignant pheno-
type.23 Genome wide analysis techniques, such as chromosome
painting, comparative genomic hybridization, representational dif-
ference analysis and restriction landmark genome scanning, have
revealed that certain oncogenes might induce genome instabil-
ity.24,25 In vitro studies made on Rat1A, Ba/F3 and primary human
fibroblast cells showed that MYC might also contribute to tumor-
igenesis by destabilizing the cellular genome.26–28
In order to study the effects of MYC activation in lymphoid
tissues, we generated a conditional mouse model based on the
tet-off system. These mice develop both T- and B-cell lymphomas.
Upon transgene inactivation, tumor cells not only enter apoptosis
but also show signs of differentiation. Furthermore, we demon-
strate that overexpression of MYC alone can induce genomic
instability.
MATERIAL AND METHODS
Generation of transgenic mice
An EcoRI-HindIII fragment that contained the human c-MYC
cDNA (exons 2 and 3, provided by M. Eilers) was inserted into the
bidirectional tetracycline-dependent expression vector pBI5,29 cre-
ating tetO-MYC; E-tTA mice used in our study were previously
described.30 In both cases, founders were derived in the NMRI
outbread background. The genotype of the transgenic animals was
determined by Southern blot and/or PCR. Animal studies were
approved by governmental review boards.
Luciferase activity measurement
Tissues from tTA/MYC mice were homogenized in extraction
buffer (100 mM K-PO4, 1% Triton X, 10 % glycerin, 2 mM EDTA
and protease inhibitors) and luciferase enzyme activities were
measured using luciferase buffer from Promega (Madison, WI) in
a luminometer (Lumat LB 9507, Berthold Technologies, Ger-
many).
Histology
Tissues were embedded in Tissue-Tek O.C.T. Compound
(Sakura, The Netherlands), snap frozen in liquid nitrogen and
stored at 80°C. Cryostat sections of 4 m were prepared, fixed
with acetone and stained with hematoxylin and eosin to investigate
tumor invasion. Apoptotic cells were detected using the Tunel
Assay Kit (Promega) according manufacturer’s instructions. Con-
ventional Giemsa staining was used to analyze bone marrow,
blood and tumor cell lines.
For the analysis of GFP expression, tissues were first fixed for
24 hr in 4% buffered formalin with 7% picric acid and 10%
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sucrose and then embedded in Tissue-Tek O.C.T. Compound.
Nuclei were stained with fluorescent dye (DAPI, 0.1 g/ml;
Roche, Switzerland).
All slides were analyzed using a Leica microscope (DMIRB/E)
and OpenLab software (version 3.1.1.). The excitation wavelength
was 470 nm for GFP and 359 nm for DAPI.
FACS analysis
Single cell suspensions from the tissues were depleted of red
cells using Lympholyte-M (Cederlane, Canada). For FACS anal-
ysis cells were blocked with anti-FcII/III receptor antibody and
stained with different combinations of CD3-FITC, TCR-biotin,
B220-PE, CD8-FITC, CD4-PE, IgD-FITC, IgM-PE, CD43-biotin,
CD23-PE, CD21-biotin, CD5-APC and Mac-1-PE antibodies (all
produced by Pharmingen, Heidelberg, Germany). Biotin-labeled
antibodies were visualized using streptavidin-CyChrome (Pharm-
ingen). The annexin V-FITC apoptosis detection kit was obtained
from Pharmingen and Annexin V and PI staining were performed
according to the manufacturer instruction. Cell surface marker
expression was analyzed using a 4-color flow cytometer (FACS-
Calibur) and Cell Quest software (Becton Dickinson, Heidelberg,
Germany).
Tumor cell lines
Tumors were prepared as single cell suspensions and adapted to
in vitro growth in RPMI1640 supplemented with 10% FCS, pen-
icillin/streptomycin, NEAA, glutamine and beta-mercaptoethanol
(all from PAN Biotech, Germany). Tumor cell line proliferation
was measured by counting Trypan blue negative cells.
Doxycycline treatment
To suppress expression of MYC transgene, mice were given
doxycycline (ICN Biomedicals, Inc., Ohio) in the drinking water at
a concentration of 100 g/ml. Tumor cell lines were treated with
2 g/ml of doxycycline for the indicated time periods.
Tumor transfers
Tumor tissues were prepared as a single cell suspension in PBS
and 107 cells were inoculated i.v. or i.p. into syngeneic mice.
Alternatively, some tumors were first adapted to in vitro growth
and infected with a retrovirus expressing GFP prior to injection.
CGH (Comparative Genomic Hybridization)
DNAs from tumor cell lines and normal mouse tissue, as refer-
ence DNA, were used. CGH was performed as previously de-
scribed.31,32 The tumor cell line DNA was labeled with biotin-16-
dUTP and normal reference DNA with digoxygenin-11-dUTP.
Labeled DNAs, each 1 g, were precipitated with 70 g unlabeled
Cot1-DNA and 30 g herring sperm DNA. The precipitate was
dissolved in hybridization buffer, denatured at 76°C for 6 min and
hybridized after pre-annealing for 3 days on normal denatured
metaphase spreads. After incubation the detection was performed
with avidin-Texas-Red and anti-digoxygenin-FITC. Counterstain-
ing was done with DAPI.
The ratio of green to red fluorescence intensities along each
chromosome was calculated by the V3.05 version of Isis software
(Metasystems, Heidelberg, Germany). Between 10 and 15 met-
aphases were analyzed per sample to ascertain copy number
changes for each cell line. A copy number change was considered
a gain when the cell line to normal (red to green fluorescence) ratio
exceeded the 1.25 cut off level and as a loss when the ratio was
below 0.8.
FISH (Fluorescence in situ hybridization)
Chromosomes of the cell lines were prepared by standard tech-
niques. Whole chromosome paints (WCP) were made according to
the manufacturer’s protocol (Cambio, Ltd., Cambridge, UK). All
BAC probes were from RPCI23 or RPCI24 libraries and purchased
at the BACPAC resource center (www.chori.org/bacpac). For flu-
orescence in situ hybridization (FISH), standard techniques were
applied.
Analysis of mRNA expression levels
Total RNA was isolated from tumor cell lines, thymocytes and
B220splenocytes using High Pure RNA Isolation Kit (Roche,
Switzerland) and reverse transcribed with M-MLV Reverse Tran-
scriptase (Invitrogen, Carlsbad, CA) and random hexamer primers
(Roche). In order to distinguish between human and mouse MYC
transcript, primers specific for both species were created and used
in PCR. For other genes from chromosome 15 specific PCR
primers were designed (all primers sequences are available upon
request). -actin primers were used as a control for a housekeeping
gene.
RESULTS
MYC overexpression in the lymphoid lineage causes T- and
B-cell lymphomas
We generated a mouse model for studying the effects of condi-
tional MYC expression in lymphoid cells using the tet-off sys-
tem.29,33 Two types of transgenic mice were established (Fig.1a).
The first line (E-tTA) expresses the tetracycline-transactivator
(tTA) under the control of the intronic Ig- heavy chain enhancer
(E) and a minimal promoter.30,34 The second line (tetO-MYC)
contains the human MYC cDNA and a luciferase reporter gene
under the control of the tetracycline responsive bidirectional pro-
moter (tetO).29 In double transgenic animals (tTA/MYC), tTA
mediates the transcription of the luciferase reporter gene and
simultaneously the MYC protooncogene. Both genes are repressed
in the presence of doxycycline.
Eight independent tetO-MYC founder lines were established
and crossed to the E-tTA line. The resulting double transgenic
mice were then initially analyzed for luciferase expression in
different organs (Fig.1b and data not shown). The highest lucif-
erase activities were observed in thymus, spleen and lymph nodes.
Nonlymphoid organs exhibited only background activity (kidney,
brain and muscles) or slightly increased expression (liver) proba-
bly because of the presence of lymphoid cells from blood. After
doxycycline treatment, luciferase activity was virtually abolished,
demonstrating the regulation of tetO-dependent transgenes (data
not shown).
FIGURE 1 – Induction of lymphomas by MYC under the control of
tet-off system. (a) Constructs for MYC expression in transgenic mice.
The tetracycline-dependent transactivator (the tet-off system) and the
tet-operator Myc-cassette (with bidirectional promoter expressing also
luciferase) are indicated. (b) Adult tTA/MYC mice were sacrificed and
luciferase activities in indicated tissues were measured. Representative
results are shown. (c) Survival rate of transgenic animals. Life span of
at least 20 animals per each group was monitored. Single transgenic or
wild-type animals were used as a control. One group of tTA/MYC
mice was given doxycycline in the drinking water (100 g/ml) starting
from 10th week of age (time when typically first signs of disease are
observed).
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Double transgenic tTA/MYC mice were born healthy with the
expected Mendelian frequencies. However, all tTA/MYC mice
from the line with the highest luciferase activity showed first
visible signs of illness at about 10 weeks of age. These mice died
within 4 months with an average life span of 13 weeks (Fig.1c).
Slow movement, ruffled fur, hunched posture and perhaps enlarge-
ment of lymph nodes manifested later phases of illness. Most of
the experiments were performed with this line. The other 7 tetO-
MYC founder lines also exhibited high luciferase expression and
they also developed lymphomas, however with somewhat delayed
schedule and lower penetrance.
Gross anatomical analyses showed the occurrence of 2 morpho-
logically distinct types of tumors in tTA/MYC mice. Type I was
characterized by enlargement of the thymus, spleen, liver and
sporadically mesenteric lymph nodes (Fig. 2a left). The features of
the type II tumors were huge inguinal, cervical and brachial lymph
nodes and an increased size of the spleen, the liver and sometimes
the thymus (Fig. 2a right).
Histological examination of animals with advanced tumors of
both types revealed tumor cells within different tissues. Splenic
architecture was largely obliterated; no clear distinction between
red and white pulp could be made (Fig. 2b). Thymus and lymph
nodes were also affected (data not shown), while large lympho-
blastic cells invaded kidney and liver where they were detected
around blood vessels. In addition to the lymphomas, we also
detected leukemic cells in bone marrow and blood (Fig. 2b,c).
To investigate a possible correlation between tumor morphology
and tumor cell type, we analyzed leukemic cells from the blood of
affected animals for expression of cell surface markers by FACS.
Out of 35 analyzed mice, 74.3% developed T-cell lymphomas,
whereas the remaining 25.7% developed B-cell lymphomas. T-cell
lymphomas corresponded to the type I of gross anatomy. The
leukemic cells were surface positive for CD3 and TCR / mark-
ers. They were either CD4CD8 double positive (84,6%) or
CD4 single positive (15.4%) (Fig.2c). B-cell lymphomas repre-
sented the type II of gross anatomy. These cells were positive for
B220, IgM and CD43, and in some cases showed low levels of
CD21 and CD5 (Fig. 2c and data not shown). We never observed
expression of CD23 and IgD (data not shown), indicating that
transformation occurred at an immature stage of B-cell develop-
ment. Both types of lymphomas were negative for myeloid marker
Mac-1 (data not shown).
Establishment of T- and B-tumor cell lines
It was possible to establish appropriate tumor cell lines of both
T- and B-cell types of lymphomas. These cell lines allowed us to
investigate the consequences of MYC inactivation at the cellular
level. Tumor cell lines were first checked for the expression of
surface markers and they exhibited the same features as the cor-
responding primary tumors from donor mice (data not shown).
Interestingly, after several weeks of in vitro culture all B-cell lines
eventually lost expression of surface IgM. Several T- and B-tumor
cell lines were checked for expression of human MYC using RT
PCR and all of them were positive (Fig. 3a). Upon treatment with
doxycycline, tumor cell lines aborted expression of human MYC
within 1 to 4 hr (Fig. 3a). This result is concordant with previously
published data indicating that MYC protein and mRNA have short
half-lives of about 30 min each.2 B- and T-tumor cell lines exhib-
ited high luciferase expression, which was reduced to background
levels upon doxycycline treatment (data not shown). These results
suggested that the activity of the luciferase reporter gene could be
used to follow the status of transgenic MYC levels in tumor cells.
FIGURE 2 – MYC overexpression in lymphoid tissues induces T and
B-cell lymphomas. (a) tTA/MYC mice with obvious signs of illness
were sacrificed and gross anatomy of organs was examined. Two types
of morphological changes corresponding to T- (type I) or B- (type II)
cell lymphomas were observed. (b) Histological examination of organs
from mice with advanced lymphomas revealed the presence of lym-
phoblastic cells in spleen, liver, kidney and bone marrow. (c) Tumor
phenotypes of T- and B-cell lymphomas corresponding to the above-
mentioned type I and II morphologies.
FIGURE 3 – MYC inactivation in vitro. (a) Tumor cell lines were
treated with doxycycline (2 g/ml) for the indicated times. After
treatment, total RNA was isolated, reverse transcribed and PCRs for
transgenic (human) MYC were performed. Examples for T- (4347-
6TH T) and B- (5542-2TH B) cell lymphomas are presented. (b–d)
Tumor cell lines were incubated with or without doxycycline for 24 hr
and then analysed for various parameters. Cell cycle was analyzed
using PI staining (b), apoptosis was measured using Annexin V stain-
ing (c) and cell morphology was determined by Giemsa staining (d).
Representative data are shown.
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Tumor cell lines of both types demonstrated exponential prolifer-
ation that was aborted by doxycycline treatment (data not shown).
Analysis of DNA content by PI staining confirmed the proliferation
arrest upon addition of doxycycline (Fig. 3b). Tumor cells treated with
doxycycline for 24 hr showed accumulation of cells in the G0/G1
phase of the cell cycle. Furthermore, MYC inactivation not only
resulted in a proliferative arrest but also in characteristic morpholog-
ical changes (Fig. 3d) and apoptosis (Fig. 3c).
Tumor regression upon inactivation of transgenic MYC
We then tested whether suppression of transgenic MYC expres-
sion in tTA/MYC mice would result in a reversal of the tumor
phenotype. Lymphoma-bearing mice at advanced stages of dis-
ease, defined by lymphoadenopathy and presence of lymphoblastic
cells in the blood, were treated with doxycycline in the drinking
water. Within 2 days of treatment, mice became physically more
active and within 1 week showed absence of lymphoadenopathy
and lymphoblastic cells in peripheral blood. All tested animals
demonstrated initial regression of tumor, while inactivation of
MYC was sufficient to induce remission for a prolonged time
period in about 70% of cases (Fig. 1c). When these tTA/MYC
mice were continuously treated with doxycycline, they reached life
span of single transgenic control animals. In parallel, we investi-
gated the rate of tumorigenic and apoptotic cells in such doxycy-
cline-treated mice (Fig. 4a). Mice positive for the presence of
tumor lymphoblastic cells in peripheral blood were chosen. Upon
doxycycline treatment, blood was checked for the amount of
tumorigenic cells (CD4CD8
 double positive cells in the case
represented) and cells that undergo apoptosis (Annexin V posi-
tive). Our results clearly show that the loss of lymphoblastic cells
is associated with increased levels of apoptosis after 3 days of
doxycycline treatment. Increased apoptosis correlated with the
reduction of the number of neoplastic cells over the following
days. Within 9 days, the tumor had entirely regressed and no tumor
cells were found in the blood after this time period. However only
sustained MYC inactivation reversed the phenotype of tTA/MYC
mice. When apparently cured mice were taken off doxycycline,
tumors reappeared in these mice within a time period of 2–3 weeks
(Fig. 4a).
It was shown that Annexin V binds with different affinities to
the surface of the lymphocytes at different stages of develop-
ment.35 To confirm that the increased proportion of Annexin V
positive cells that appeared after doxycycline treatment did indeed
represent apoptotic cells, we performed Tunel Assays. Spleen
sections of tumor-bearing mice, which were either untreated or
treated with doxycycline, were analyzed (Fig. 4b). Our results
showed high levels of apoptosis after 4 days of treatment with
doxycycline. In contrast, only a few apoptotic cells were seen in
untreated mice.
To demonstrate that enlarged organs in tTA/MYC mice repre-
sent real tumors rather than a massive proliferation of activated
cells, we transplanted several of the tumors to healthy syngeneic
mice. Single cell suspensions were made from primary tumor
tissues and either injected directly into recipient mice or they were
previously cultured in vitro. Within 2 weeks mice injected with T-
or B-cell lymphomas developed tumors, which expressed the same
cell surface markers as the donor tumors (data not shown). Syn-
geneic mice with transplanted tumors recapitulated the pattern of
tumor invasion of primary transgenic tumors (data not shown).
Similarly to the results obtained with the original MYC transgenic
mice, transplanted tumors rapidly regressed upon doxycycline
treatment, while nontreated animals died as a consequence of
aggressive lymphomas (Fig. 4c).
Differentiation as a mechanism of tumor elimination
Previously described data suggested that apoptosis and differ-
entiation are the main mechanisms responsible for tumor elimina-
FIGURE 4 – Tumor cells undergo apoptosis upon doxycycline treat-
ment. (a) Lymphoma-bearing mice were treated with doxycycline (100
g/ml in drinking water) for the indicated time. Mice were daily bled
before (day 0) and during doxycycline administration and FACS analysis
of blood was performed. After 9 days doxycycline treatment was canceled
and the mice were bled after an additional 20 days. Representative results
showing percentage of tumorigenic (CD4/CD8) and apoptotic (An-
nexin V) cells in gated lymphocytes are presented. (b) TUNEL assays
revealed apoptosis in the spleen of tumor-bearing mice treated with
doxycycline. Slides were counterstained with DAPI. (c) 107 lymphoma
cells were transplanted into syngeneic wild-type recipients. One group of
recipients was treated with doxycycline (100 g/ml in drinking water)
immediately upon injection of lymphoma cells. Survival rate of mice (6
per group) is presented.
FIGURE 5 – GFP labeled tumor cell lines as a model for examination
of the differentiation status Syngeneic recipients were injected with a
tumor cell line (107 cells), which had been labeled with GFP using
retroviral gene transfer. (a) After 10 days, mice were sacrificed,
sections from liver and spleen were made, stained with DAPI (blue)
and analyzed for the presence of GFP cells (green). (b) 10 days after
transplantation 1 group of recipient mice was doxycycline treated for
5 days (100 g/ml in the drinking water). Expression of surface
markers on isolated GFP; cells from treated mice was compared to
the expression levels on GFP cells isolated from the untreated group.
The gray line represents the staining control (unstained cells in CD5
and Mac-1 staining and Cy-chrome in CD43, CD23 and CD21 stain-
ing). Data are representative for 3 mice per group.
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tion in MYC transgenic mice.20 In order to investigate whether
differentiation occurs as a consequence of doxycycline treatment,
we used GFP to mark the tumor cells. Retroviral gene transfer was
used to express the GFP protein in some of the tumor B-cell lines.
Such GFP marked cells were then injected into syngeneic mice.
This approach allowed us to distinguish neoplastic cells from
normal recipient’s lymphocytes. Recipients again developed ag-
gressive lymphomas that invaded different lymphoid and nonlym-
phoid organs. We were able to detect GFP positive cells in histo-
logical sections from spleen and liver (Fig. 5a) but also by FACS
analysis in blood, lymph nodes and spleen (data not shown).
Analysis of the surface marker expression profile revealed that the
GFP-labeled tumor cell line expressed significant amounts of
CD21 and CD43, while the level of CD23 was low (Fig. 5b). As
already mentioned, during the in vitro cultivation period the B cells
lost expression of surface IgM. This IgM expression did not
reappear in the transplanted tumors. CD5 was expressed on the
surface of these cells; however we could not detect presence of
Mac-1, indicating that these cells were not canonical B1 B cells
(Fig. 5b). The identical patterns of cell surface marker expression
were detected on cells before and after GFP labeling as well as
after injection into the syngeneic mice (data not shown and Fig.
5b). After tumors had developed in recipient mice, 1 group of mice
was treated with doxycycline, and 5 days later, the GFP positive
cells were analyzed and compared to those from untreated animals.
In line with earlier data,20 doxycycline treatment led to a reduction
in the size of tumor cells (Fig. 5b). Interestingly however, surface
marker expression also changed upon treatment. We observed a
reduction of CD43 as well as of CD5 expression levels (Fig. 5b),
indicating that downregulation of transgenic MYC could indeed
induce differentiation. However, while expression of CD21 was
slightly increased, the level of CD23 was not significantly altered
by MYC inactivation and we were not able to detect IgM or IgD
on the cell surface. Thus these cells exhibit only a partial progres-
sion along the B-cell differentiation pathway.
Genome instability in tumor cell lines
Several in vitro analyses had shown that MYC activation in-
duces the rapid accumulation of chromosomal abnormalities.26–28
We therefore asked whether MYC was able to induce genomic
instability in our in vivo model of lymphomagenesis. To answer
this question, we performed CGH (Comparative Genomic Hybrid-
ization) analysis. DNAs from different T- and B-lymphoma cell
lines and normal reference DNA were isolated, labeled and hy-
bridized to normal denatured metaphase spreads. In all analyzed
tumor samples, chromosomal aberrations in the form of loss or
gain of chromosomal material were detected (data summarized in
Table I). The most common finding was a gain of chromosome 15
in T-cell tumors. In 4 out of 7 independently established cell lines
from different animals that had developed T-cell lymphoma, this
gain of chromosome 15 sequences was observed. The gain of
chromosome 15 was present in all cell lines made from the same
animal, no matter from which organ the line was derived and no
matter how many passages the cells were cultured [from mouse
4347-6 lines: 4347-6SP (T), 4347-6TH (T)-a and 4347-6TH (T)-b
and from mouse 7755-4 lines: 7755-4TH (T)-a and 7755-4 TH
(T)-b]. The gain of chromosome 15 was not observed in any of the
B-cell lymphomas analyzed. In the case of 2 cell lines [4347-6TH
(T) and 7755-4TH (T)] that were analyzed for the second time
after increased number of passages, additional chromosomal alter-
ations were found.
A whole chromosome paint (WCP) of chromosome 15 showed
that the detected gains of chromosome 15 actually represented
trisomy of this chromosome (Fig. 6a). All 3 copies of chromosome
15 seem to be normal as no gross structural differences were
detectable. This result was further confirmed by 2-color FISH
hybridizations with different combinations of BAC probes specific
for genes, which are all localized at 62.4–103.9 Mb on chromo-
some 15 such as MYC, Tgn, Pdgf2, Ly6, Itgb7 and the Hox gene
cluster (data not shown).
Expression of chromosome 15 related genes
To determine whether trisomy of chromosome 15 leads to
increased expression of endogenous (mouse) MYC, we compared
the expression levels of MYC mRNA in the samples of the T-cell
lines with and without chromosome 15 trisomy as well as in the
B-cell lines. As a control, mRNA from wild-type mouse thymo-
cytes or splenic B cells was used. While in the control samples
mouse MYC mRNA was clearly present, we were not able to
detect murine MYC mRNA in any of the tested tumor cell lines
made from tTA/MYC mice (Fig. 6b). This result is in agreement
with previously published data showing that transgenic MYC
results in repression of the endogenous MYC gene.19
In addition to the MYC gene, chromosome 15 contains several
additional genes with known functions in lymphocyte proliferation
and/or tumorigenesis. We analyzed mRNA levels of IL-2 receptor
FIGURE 6 – MYC overexpression leads to genomic instability. (a)
Cell lines with the observed gain of chromosomal material correspond-
ing to chromosome 15 by CGH analysis were subjected to fluores-
cence in situ hybridization (FISH) using whole chromosome 15
probes. The representative result shows chromosome 15 trisomy in 1
of the analyzed tumor cell lines. (b) RNA was isolated from T-cell
lines with or without chromosome 15 trisomy, as well as B-cell lines.
RT-PCR analysis of the indicated genes was performed. As a control
wild-type thymocytes or B-cell-enriched splenocytes were used. Prim-
ers specific for -actin were used as control.





1749-2SP (T) 3; 15
3445-2TH (T) 11A4-E; 14A-C
4347-6SP (T) 15
4347-6TH (T)-a 15
4347-6TH (T)-b 3D-F; 15
4491-8TH (T) 10; 15 1C3-D
4502-8TH (T) 12A-C2




7755-4TH (T)-b 10B-D; 15
1Several T- and B-cell lymphoma lines, (T) or (B), were analyzed
for chromosomal instabilities. Tumor cell lines 4347-6SP (T) and
4347-6TH (T), and lines 5532-2SP (B) and 5532-2TH (B) were
derived from the same mouse respectively (mouse 4347 and mouse
5532) but were established from different organs (SP-spleen, TH-
thymus). Also 2 lines were analyzed for a 2 time after additional
number of passages (-a for the first analysis and -b for the second
analysis).
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beta (IL-2R), IL-7 receptor, retinoic acid receptor gamma (RAR
), Wnt 1, SLAP and cyclin B1 in order to investigate whether
expression of these molecules was altered thus contributing to the
MYC-induced lymphomagenesis. Compared to control cells, all
tumor cell lines expressed increased levels of cyclin B1. Further-
more IL-7R mRNA expression was high in all B-cell lines and
some of the T-cell lines (Fig. 6b). No obvious difference was
observed in the case of SLAP and Wnt 1 genes (Fig. 6b). Intrigu-
ingly, expression of mRNA for IL-2 receptor beta was completely
blocked in tumor cells (Fig. 6b). Since IL-2R signaling was
shown to regulate expression of MYC,36,37 this result suggests that
reduction of IL-2R expression could be part of the feedback
mechanism by which cells regulate MYC protein levels. Interest-
ingly, while expression of virtually all of these genes differed
between wild-type and tumor cells, we did not observe any sig-
nificant difference between tumor cell lines with and without
chromosome 15 trisomy.
DISCUSSION
Association of MYC expression with tumorigenesis in various
tissues is consistent with the crucial role for this oncogene in the
regulation of cell growth and development. Different MYC transgenic
models established in the past confirmed this hypothesis. It has been
shown that elevated MYC expression could result in a variety of
tumors including testicular tumors,  cell tumors in the pancreas,
papillomatosis and mammary adenocarcinomas.21,38–40 Many efforts
have been made to develop mouse model of MYC-induced leuke-
mias. While some of these models used promoters expressed in wide
variety of tissues,38 others were based on the E enhancer similar to
our study. Felsher and Bishop employed a very similar strategy to
control MYC expression in lymphoid tissues.20 While in most E-
MYC based models, elevated expression of MYC led to the devel-
opment of B-cell lymphomas, they found predominantly T-cell lym-
phomas and some myeloid leukemias.20 In contrast, our mice
developed both T- and B-cell lymphomas although the latter to a
lower extent. The expression cassette used to drive tTA in our mice
had been studied earlier and it had been shown to function efficiently
in bone marrow, thymus, spleen and lymph nodes.34 The fact that the
highest luciferase activities were observed in the thymus might ex-
plain the prevalence of T-cell lymphomas in our study.
We could show that lymphomas that developed in our model
were transplantable, thus proving that accumulation of lympho-
cytes in the lymphoid organs and the blood of tTA/MYC mice was
not due to an increased proliferation of the reactive cells but indeed
due to MYC-induced tumorigenesis. Furthermore, cells isolated
from transgenic mice could be easily adapted to the growth in cell
culture without any specific growth factors.
Gross anatomy of affected mice demonstrated a dual origin of
developed lymphomas with characteristic histological features of the
B- and T-cell lymphomas, respectively. Tumor cells exhibited hall-
marks of early stages of lymphocyte development. T-cell lymphomas
were mostly CD4/CD8 double positive with only 15% of them being
CD4 single positive. The B-cell lymphomas we observed resembled
those described in a mouse model of Burkitt lymphoma.22 They
expressed IgM and CD43 and very low levels of CD23. However,
opposite to Burkitt lymphoma cell lines, our B-cell lymphomas lost
surface IgM after in vitro cultivation. This phenotypic instability
could suggest that in our mice MYC-induced transformation had
occurred at an earlier stage of B-cell development.
Treatment of tumor-bearing mice or established cell lines with
doxycycline demonstrated that all lymphomas were dependent on
continuous MYC expression. In the presence of doxycycline, cells
rapidly lose expression of transgenic MYC protein and this results
in growth arrest at the G1 stage of cell cycle and induction of
apoptosis. Tumor regression and apoptosis were also readily ap-
parent in mice after MYC inactivation. The correlation between
increased apoptosis and reduction of tumor cell numbers indicates
that apoptosis is a major mechanism of tumor elimination. Fur-
thermore, Felsher and Bishop20 had interpreted morphological
changes of tumor cells upon MYC inactivation as evidence for
cellular differentiation. Our data also strengthen this latter hypoth-
esis. The GFP-labeled B-cell lymphoma cells used in our study did
not reach the stage of terminal maturation. It is well documented
that development of B cells depends on BCR signaling.41 There-
fore, the observed loss of surface IgM during in vitro cultivation of
B cell most likely limited their ability to accomplish terminal
differentiation. Nevertheless, the alterations in CD43 and CD21
surface expression levels indicate that the cells proceeded at least
partially in their differentiation upon MYC inactivation.
Induction of genomic instability by MYC overexpression was
already postulated according to the data obtained in different in vitro
models. It was described that MYC can induce genomic instability in
vitro in IL-3 dependent murine Ba/F3 cells27 and in the Rat1A cell
line defective for the ARF/MDM2/p53 pathway.26 The same effect of
MYC was also shown in cell culture of normal human fibroblasts.28
Similar findings were obtained in ex vivo analyses of MYC transgenic
mice on a p53-deficient background.42 In line with this, our data show
the ability of MYC alone to induce genomic instability in vivo.
Interestingly, it seems that genomic instability induced by MYC are
not randomly distributed throughout the genome. We could observe
that in several cell lines chromosomes 1, 3, 10 and 14 were affected.
Abnormalities of chromosomes 1 and 14 as a consequence of MYC
action were already described in BALB/c mice prone to development
of plasmacytomas.43 Importantly, we found that more than 50% of the
T-cell lymphomas analyzed have an additional copy of chromosome
15. The gain of chromosomal material that corresponds to chromo-
some 15 has been frequently observed in different mouse tumor
models.44 Often, this gain was due to amplification of MYC itself and
has been considered as directly responsible for tumor develop-
ment.44–46 We observed a complete trisomy of chromosome 15 but
no increased copy number of the endogenous MYC gene or any of
other analyzed genes. The presence of an additional copy of chromo-
some 15 in tTA/MYC mice in fact does not lead to increased amounts
of mouse MYC mRNA. In contrast, we were not able to detect
mRNA encoding endogenous MYC in any of analyzed cell lines. This
finding confirms earlier results that the MYC gene is subjected to
negative feedback control by an excess of transgenic MYC.19,47,48
We also analyzed mRNA expression of several others genes
located at chromosome 15 that might have a role in the regulation
of cell proliferation and differentiation as well as in tumorigenesis.
Although we observed differences between tumor and wild-type
cells, no consistent differences in expression of those genes were
observed between the samples of tumor cells with and without
chromosome 15 trisomy.
The significance of genomic instability in MYC-induced tumori-
genesis still is not resolved. Different authors suggest genomic insta-
bility as a crucial step in tumorigenesis.26 In contrast, others consider
it as a side-step and consequence of neoplastic process.28 Complete
dependence of developed tumors in tTA/MYC mice on sustained
MYC activation could argue in favor of the latter opinion. However,
previous studies described MYC induced tumors as monoclonal.18,20
Our findings that we never observed different lymphoma types in 1
mouse and the observation that same types of genomic instabilities
were detected in tumor cells isolated from different organs of 1 mouse
also imply tumor monoclonality. Additionally, we did not observe any
alteration in size and cellularity of lymphoid organs in preneoplastic
mice. Together, these data suggest that although tumors were MYC
dependent, additional events are clearly necessary for MYC-induced
neoplastic transformation. Although genomic instability seems to be
important element of MYC-triggered tumorigenesis, we do not know
the exact nature of these further events.
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